2 completed, 1 unknown, 1 withdrawn. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 3 | 1 | Unknown 1 |
Follow MGC Pharmaceuticals d.o.o: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies MGCND00EP1, Placebo, ECG - Resistant Epilepsy, Drug, Adolescent Epilepsy | Phase 2 | Withdrawn | MGC Pharmaceuticals d.o.o | 2024-05-30 | 2024-06-03 | |
| Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 Biochemistry blood test, Hematology blood test, D-Dimer test (coagulation) - Covid19, Corona Virus Infection | Phase 2 | Completed | MGC Pharmaceuticals d.o.o | 240 | 2022-10-11 | 2023-03-15 |
| Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 Placebo administration, Confirm SARS-CoV-2 infection, Physical Examination - Corona Virus Infection, Covid19 | Phase 3 | Unknown | MGC Pharmaceuticals d.o.o | 252 | 2021-06-11 | 2022-08-24 |
| A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 ArtemiC, Placebo - COVID-19, Corona Virus Infection | Phase 2 | Completed | MGC Pharmaceuticals d.o.o | 50 | 2020-05-08 | 2021-08-31 |
COVID-19 (3) · Coronavirus Infections (3) · Drug Resistant Epilepsy (1) · Epilepsy (1) · Severe Acute Respiratory Syndrome (1)
Electrocardiography (2) · Hematologic Tests (2) · Pregnancy Tests (2) · Blood Coagulation (1) · Blood Specimen Collection (1) · COVID-19 Testing (1) · Electroencephalography (1) · Pharmacokinetics (1) · Physical Examination (1) · Restraint, Physical (1) · Urine Specimen Collection (1) · Vital Signs (1) · nabiximols (1)
Israel (4) · India (1) · Slovenia (1)
Rubi Zomer (2) · Rita Nadaf (1)